Italia Mascaro

Italia Mascaro

Auto-generated profile, based on publicly available information

Italia Mascaro

Department of Medical and Surgical Sciences, Pediatric Unit, University “Magna Graecia” of Catanzaro, Catanzaro, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2013 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
FCFerdinando Ceravolo
Ferdinando Ceravolo
IMItalia Mascaro
Italia Mascaro
SSSimona Sestito
Simona Sestito
EPElisa Pascale
Elisa Pascale
ALAntonino Lauricella
Antonino Lauricella
DCDaniela Concolino
Daniela Concolino
Hunter syndrome (mucopolysaccharidosis type II [MPS II], OMIM309900) is a rare X-linked lysosomal storage disorder caused by the deficiency of the enzyme iduronate-2-sulphatase, resulting in accumulation of glycosaminoglycans, progressive multisystem organ failure, and early death. Enzyme replacement therapy (ERT) with weekly intravenous infusions of idursulfase, a treatment for MPS II and commercially available since 2007, has been shown to improve certain symptoms and signs of the disease. The efficacy and safety data of this enzyme preparation have been widely reported and, after a change to the idursulfase Summary of Product Characteristics in March 2010, home ERT by infusion is now an option for selected patients. Previously reported experiences of home therapy in MPS II have shown increased treatment compliance and an improvement in quality of life for both patients and families. We report the results of the home therapy experience of 3 paediatric patients with MPS II in southern Italy. This pilot experience with home infusion is the first reported from Italy.

21 June 2013 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
MRM. Rapsomaniki
M. Rapsomaniki
Giuseppe ChiarellaGiuseppe Chiarella
Giuseppe Chiarella
IMI. Mascaro
I. Mascaro
FCF. Ceravolo
F. Ceravolo
ECE. Cassandro
E. Cassandro
DCDaniela Concolino
Daniela Concolino

1 March 2016 in Journal of Pediatric Biochemistry
Verified
Journal Article
Closed access
PDF file
IMItalia Mascaro
Italia Mascaro
FCFerdinando Ceravolo
Ferdinando Ceravolo
SFStefania Ferraro
Stefania Ferraro
DPDaniela Procopio
Daniela Procopio
FFFrancesca Falvo
Francesca Falvo
DCDaniela Concolino
Daniela Concolino
Tetrahydrobiopterin (BH4) is a natural and essential cofactor for the enzymatic hydroxylation of phenylalanine (Phe) and tyrosine (Tyr), and for two tryptophan hydroxylases, three nitric oxide synthases, and glyceryl-ether monooxygenase. Five separate genetic conditions affecting BH4 synthesis or recycling have been identified so far, including deficiency in (1) 6-pyruvoyltetrahydropterin synthase; (2) dihydropteridine reductase; (3) GTP cyclohydrolase I; (4) sepiapterin reductase; and (5) pterin-4α-carbinolamine dehydratase. These disorders cause hyperphenylalaninemia and impaired synthesis of serotonin and dopamine since tyrosine hydroxylase and neuronal tryptophan hydroxylase require BH4 and serotonin/dopamine products (5-hydroxytryptophan and L-dopa). All these five genetic conditions can be identified by newborn screening procedures due to elevated blood levels of Phe (with the sole exception of sepiapterin reductase deficiency). BH4 loading tests and measurement of neurotransmitter metabolites, pterins, and folates in cerebrospinal fluid can add further important information on disease severity. Untreated patients develop a complex neurological phenotype, which includes Parkinson-like features, brain degeneration, and early death. The gold standard treatment of severe disorders of BH4 metabolism is based on replacement therapy with BH4, 5-hydroxytryptophan, L-dopa, and carbidopa, with the addition, in certain cases, of folinic acid supplements and pramipexole. Dopamine agonists can improve L-dopa therapy, making treatment easier, relieving symptoms, stabilizing clinical course, and possibly ameliorating long-term outcomes. The outcome of patients with disorders of biopterin synthesis can be favorable, with either normal or near-normal cognition, and with some residual neurological symptoms usually manifesting diurnal variation, that is, worst when patients become tired or when the dosage or interval for medications is inadequate.

1 March 2016 in Journal of Pediatric Biochemistry
Verified
Journal Article
Closed access
PDF file
FFFrancesca Falvo
Francesca Falvo
ANAngela Nicoletti
Angela Nicoletti
MGMichele Grisolia
Michele Grisolia
IMItalia Mascaro
Italia Mascaro
EPElisa Pascale
Elisa Pascale
SSSimona Sestito
Simona Sestito
The mucopolysaccharidoses (MPSs) are a group of rare lysosomal storage disorders caused by deficiency of enzymes catalyzing the stepwise degradation of glycosaminoglycans dermatan sulfate, heparan sulfate, keratan sulfate, chondroitin sulfate, and hyaluronic acid. There are seven groups of MPS, which are MPS-I (MPS-I-H or Hurler syndrome; MPS-I-S or Scheie syndrome; and MPS-I-HS or Hurler–Scheie syndrome), MPS-II (Hunter syndrome), MPS-III (Sanfilippo syndrome types A to D), MPS-IV (Morquio syndrome types A and B), MPS-VI (Maroteaux–Lamy syndrome), MPS-VII (Sly syndrome), and MPS-IX (Natowicz syndrome). All are inherited as autosomal recessive diseases, with the exception of Hunter syndrome, which follows an X-linked recessive inheritance pattern. The MPSs affect multiple organ systems (including bone, heart, and visceral organs), leading to organ failure. Involvement of central nervous system occurs only in the forms with heparan sulfate accumulation, that is, MPS-I, MPS-II, MPS-III, and MPS-VII. Therapy is available for MPS-I, MPS-II, MPS-IV, and MPS-VI. This review provides a case-based overview of the different forms of MPS with neurological involvement.

1 March 2016 in Journal of Pediatric Biochemistry
Verified
Journal Article
Closed access
PDF file
DPDaniela Procopio
Daniela Procopio
IMItalia Mascaro
Italia Mascaro
SFStefania Ferraro
Stefania Ferraro
FCFerdinando Ceravolo
Ferdinando Ceravolo
MMMaria Teresa Moricca
Maria Teresa Moricca
DCDaniela Concolino
Daniela Concolino
Hyperphenylalaninemia (HPA) is a biochemical condition characterized by mildly or strongly elevated concentrations of the amino acid phenylalanine (Phe) in the blood. HPA is commonly diagnosed by newborn screening. The primary cause of HPA is phenylketonuria (PKU), an inborn error of metabolism characterized by persistently elevated plasma concentrations of Phe secondary to a total or partial deficiency of the liver enzyme phenylalanine hydroxylase. The treatment of babies affected with PKU is based on a Phe-restricted diet, aiming to maintain blood Phe concentrations within a range of 120 to 360 μmol/L to prevent the spectrum of neurological disorders associated with PKU, that is, microcephaly, learning disability, epilepsy, pyramidal and extrapyramidal signs, and behavioral changes. This metabolic disorder mainly affects the white matter (e.g., dysmyelination, demyelination, and hypomyelination) and the cortical-subcortical structures. A delay in starting the dietary treatment, or an inadequate Phe-restricted diet, may relentlessly lead to brain damage.

1 March 2016 in Journal of Pediatric Biochemistry
Verified
Journal Article
Closed access
PDF file
ANAngela Nicoletti
Angela Nicoletti
SSSimona Sestito
Simona Sestito
FFFrancesca Falvo
Francesca Falvo
IMItalia Mascaro
Italia Mascaro
MMMaria Teresa Moricca
Maria Teresa Moricca
DCDaniela Concolino
Daniela Concolino
Anderson-Fabry disease (AFD) is an X-linked lysosomal storage disorder caused by mutations in the α-galactosidase A gene on chromosome Xq22, resulting in α-galactosidase A enzyme deficiency. It is characterized by progressive accumulation of lipids (e.g., globotriaosylceramide) in the lysosomes of a variety of cell types, including neural cells. Neurological manifestations, other than cerebrovascular accidents, include small fiber neuropathy and dysautonomic disorders. Small fiber peripheral neuropathy often is clinically manifested at young ages. Peripheral pain can be chronic and/or can occur as provoked attacks of excruciating pain. Manifestations of dysfunction of small autonomic fibers may include impaired sweating, gastrointestinal dysmotility, and abnormal pain perception. Patients with AFD often remain undiagnosed until the emergence of a more typical clinical manifestation, characterized by chronic renal and cardiac failure. Early clinical benefits of enzyme replacement therapy include reduction of neuropathic pain, and adequate management of residual pain to a tolerable and functional level, which can substantially improve the quality of these patients. Thus, it is important that physicians consider AFD in the differential diagnosis of neurological manifestations to provide an appropriate diagnostic and therapeutic workup.